In vitro and in vivo, activated JNK signaling enriches METTL3-mediated m6 A in the 3’-UTR of PD-L1 mRNA by binding c-Jun to the METTL3 promoter, allowing PD-L1 mRNA to be recognized by the m6A reader, IGF2BP1, to mediate RNA stability and PD-L1 expression levels that This in turn resists cytotoxicity of CD8+T cells and promotes tumor immune escape. Here, METTL3 is linked to neoplasm.